Literature DB >> 28030918

To treat or not to treat drug-refractory epilepsy by the ketogenic diet? That is the question.

Marzena Ułamek-Kozioł1, Ryszard Pluta2, Anna Bogucka-Kocka3, Stanisław J Czuczwar4.   

Abstract

Epilepsy is a serious neurologic disorder worldwide which affects about 1% of the population (ca. 50 million people), the highest prevalence occurring in both children and elderly. Apart from idiopathic forms, etiology of the disease involves multiple brain risk factors - the most frequent being cerebrovascular diseases, tumours and traumatic injuries. Several treatment options exist, including, for instance, pharmacotherapy, vagal nerve stimulation or epilepsy surgery. In spite of treatment, about 30% of patients with epilepsy still have seizures and become drug-refractory. This is why other treatment options may be recommended, and ketogenic diet seems a last-chance method, especially in children and adolescents with epilepsy. The diet contains high amounts of fat and low carbohydrates with vitamin supplementation. The elevated concentrations of ketones induced by the diet may result in inhibition of the synaptic activity of glutamate, the mammalian target of the rapamycin pathway, and activation of adenosine triphosphate-sensitive potassium channels. One of the main ketones is acetone, shown to increase the seizure threshold and potentiate the anticonvulsant activity of some antiepileptic drugs. The clinical effectiveness of the ketogenic diet has been confirmed in a number of clinical trials carried out mainly on children. A wider use of the ketogenic diet may be limited by the number of early adverse effects (gastrointestinal distress, acidosis, hypoglycaemia, dehydration and lethargy), and late adverse effects (hyperuricaemia, hyperlipidaemia, kidney stones, easy bruising, and decreases in height and weight). Recently, data are available on the negative impact of the ketogenic diet on the qualitative characteristics of lipoprotein subfractions which points to the atherogenic fenotype as a new side-effect. In conclusion, future research directed to the proper identification of patients (in terms of age, epilepsy type and duration, recommended antiepileptic drugs) is necessary to answer the title question.

Entities:  

Mesh:

Year:  2016        PMID: 28030918     DOI: 10.5604/12321966.1226841

Source DB:  PubMed          Journal:  Ann Agric Environ Med        ISSN: 1232-1966            Impact factor:   1.447


  8 in total

Review 1.  Are therapeutic diets an emerging additional choice in autism spectrum disorder management?

Authors:  M Gogou; G Kolios
Journal:  World J Pediatr       Date:  2018-05-30       Impact factor: 2.764

Review 2.  Impact of Dietary Fats on Brain Functions.

Authors:  Rosanna Chianese; Roberto Coccurello; Andrea Viggiano; Marika Scafuro; Marco Fiore; Giangennaro Coppola; Francesca Felicia Operto; Silvia Fasano; Sophie Laye; Riccardo Pierantoni; Rosaria Meccariello
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

Review 3.  Ketogenic Diet in Alzheimer's Disease.

Authors:  Marta Rusek; Ryszard Pluta; Marzena Ułamek-Kozioł; Stanisław J Czuczwar
Journal:  Int J Mol Sci       Date:  2019-08-09       Impact factor: 5.923

Review 4.  Novel Cellular Functions of Very Long Chain-Fatty Acids: Insight From ELOVL4 Mutations.

Authors:  Ferenc Deák; Robert E Anderson; Jennifer L Fessler; David M Sherry
Journal:  Front Cell Neurosci       Date:  2019-09-20       Impact factor: 5.505

Review 5.  Ketogenic Diet and Epilepsy.

Authors:  Marzena Ułamek-Kozioł; Stanisław J Czuczwar; Sławomir Januszewski; Ryszard Pluta
Journal:  Nutrients       Date:  2019-10-18       Impact factor: 5.717

6.  Effects of Ketogenic Diet on Neuroinflammation in Neurodegenerative Diseases.

Authors:  Ziying Jiang; Xi Yin; Miao Wang; Tong Chen; Yuanyuan Wang; Zhongbao Gao; Zhenfu Wang
Journal:  Aging Dis       Date:  2022-07-11       Impact factor: 9.968

7.  Safety of β-hydroxybutyrate salts as a novel food pursuant to Regulation (EU) 2015/2283.

Authors:  Dominique Turck; Torsten Bohn; Jacqueline Castenmiller; Stefaan De Henauw; Karen Ildico Hirsch-Ernst; Alexandre Maciuk; Inge Mangelsdorf; Harry J McArdle; Androniki Naska; Carmen Pelaez; Kristina Pentieva; Alfonso Siani; Frank Thies; Sophia Tsabouri; Marco Vinceti; Francesco Cubadda; Thomas Frenzel; Marina Heinonen; Miguel Prieto Maradona; Rosangela Marchelli; Monika Neuhäuser-Berthold; Morten Poulsen; Josef Rudolf Schlatter; Henk van Loveren; Océane Albert; Tilemachos Goumperis; Helle Katrine Knutsen
Journal:  EFSA J       Date:  2022-10-13

8.  To treat or not to treat Alzheimer's disease by the ketogenic diet? That is the question.

Authors:  Marzena Ulamek-Koziol; Ryszard Pluta
Journal:  Neural Regen Res       Date:  2020-05       Impact factor: 5.135

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.